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Several polymorphisms of drug-metabolizing enzymes have been implicated in the
susceptibility to tumor development. The role of the CYP2D6, GSTM1 and GSTT1
genes has been extensively studied, with alleles conferring different metabolic
efficiencies and tumor risk. We studied the relationship between the main polymorphisms
of these genes and the susceptibility to develop pituitary tumors, by performing a
case-control study comprising 235 patients and 256 controls which were genotyped by
means of PCR-RFLP based assays. Frequencies of the CYP2D6*1 and of the poor
metabolizer allele CYP2D6*4, were determined along with the frequencies of the GSTM1
and GSTT1 null genotypes. CYP2D6 genotype frequencies were similar in patients and
controls (p=0.087). CYP2D6*1 and CYP2D6*4 allele frequencies were 83.8%, 16.2% in
cases and 78.3%, 21.7% in controls, showing a significant difference between the two
groups (p=0.012). There were no significant differences between the frequencies of the
GSTM1 and GSTT1 null genotypes in both groups. No association was found between
histological type and any of the studied polymorphisms. Our data suggest an association
of the CYP2D6*1 allele and the susceptibility to pituitary adenomas, which could be
due to an increased metabolism of unidentified procarcinogens or to linkage
disequilibrium with another gene involved in pituitary tumorigenesis.
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S U M M A R Y
R E S U M O
POLIMORFISMOS DO GENE CYP2D6 ESTÃO ASSOCIADOS A UMA
SUSCEPTIBILIDADE PARA OS TUMORES DA HIPÓFISE
Enzimas envolvidas no metabolismo de genotóxicos têm sido associadas a uma
susceptibilidade para alguns tumores. Existe um marcado polimorfismo de genes
codificadores destas enzimas a que corresponde diferentes capacidades metabolizadoras
que podem conferir diferentes graus de susceptibilidade para esses tumores. Neste
estudo pretendeu-se avaliar o papel dos polimorfismos dos genes CYP2D6, GSTM1 e
GSTT1 na susceptibilidade individual para o desenvolvimento de tumores da hipófise
tendo sido estudados 235 doentes com diferentes macroadenomas hipofisários e 256
controlos. Foram determinadas as frequências CYP2D6*1, CYP2D6*4, bem como a
dos genótipos nulos GSTM1 e GSTT1. As frequências genotípicas do gene CYP2D6
foram idênticas nos doentes e controlos (p=0,087). As frequências alélicas CYP2D6*1
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INTRODUCTION
Individual susceptibility for the development of tumors
depends on a complex interaction between genetic and en-
vironmental factors1,2. Susceptibility to chemical carcino-
gens plays an important role in the development of many
neoplasias. Several polymorphisms of human drug-
-metabolizing enzymes influence this individual suscepti-
bility. Among the most studied polymorphic genes that have
been associated with several tumors are the CYP2D6,
GSTM1 and GSTT1 genes3,4. The cytochrome P450 family
(including the CYP2D6) and the glutathione-S-transferases
µ1 and θ1 (GSTM1 and GSTT1) are important enzymes of
phase I and phase II, respectively, of detoxification of many
potential carcinogenic and mutagenic products5,6. The
genes that encode these enzymes are highly polymorphic
with alleles conferring different efficiencies and possibly
tumor risk. The most frequent inactivating mutation of the
CYP2D6 gene is the splice site c.506,-1g>a transition
(CYP2D6*4). Poor metabolizer (CYP2D6*4/ CYP2D6*4),
in which both alleles have inactivating mutations, and ex-
tensive metabolizer (CYP2D6*1/CYP2D6*1 or CYP2D6*1/
CYP2D6*4) genotypes have been associated with differ-
ent risks of certain pathologies including lung cancer and
others7,8. The GSTM1 and GSTT1 genes are also polymor-
phic and they have a null allele variant in which the entire
gene is absent. The null genotype for both enzymes
(GSTM1*0/GSTM1*0 and GSTT1*0/GSTT1*0) has been
associated with many different types of tumors (7-9). The
role of these genes in the development of pituitary tumors
is unknown with only two small studies described in the
literature (10,11). In order to achieve a better insight into the
relationship between the main genetic polymorphisms of
CYP2D6, GSTM1 and GSTT1 genes and the individual
susceptibility to develop pituitary tumors, we performed a
case-control study and established the frequencies of the
CYP2D6, GSTM1 and GSTT1 most common genotypes in
patients with different pituitary adenomas.
e CYP2D6*4 foram 83,8%, 16,2% nos doentes e 78,3%, 21,7% nos controlos,
evidenciando uma diferença significativa entre os dois grupos (p=0,012). As
frequências dos genótipos nulos GSTM1 e GSTT1 foram idênticas nos doentes e
controlos. Não se observou qualquer associação entre os polimorfismos estudados e
o tipo histológico do tumor. Estes resultados sugerem uma associação entre o genótipo
CYP2D6*1 e susceptibilidade para os tumores da hipófise cujo mecanismo se poderá
dever quer a um aumento da metabolização de um procarcinogénio desconhecido ou a
um desequilíbrio de ligação com outro gene envolvido no processo de génese tumoral.
Palavras-chave: tumores da hipófise e polimorfismos dos genes CYP2D6, GSTM1 e GSTT1
POPULATION AND METHODS
Studied populations and tumor classification
A retrospective case-control study was performed in-
volving a total of 491 individuals. We identified 235 cases,
(84 males, 151 females, mean age±SD 50.1±15.3 years) com-
prising adenomas of various histologies (65 null cell ad-
enomas, 64 somatotrophinomas, 58 macroprolactinomas,
27 corticotrophinomas, 12 gonadotrophinomas, 2
thyrotrophinomas and 2 pluri-hormonal adenomas. In 5 it
was not possible to perform the immunohistochemical
study, so they were classified as clinically nonfunctioning
adenomas. The diagnosis of these tumors was initially
based on clinical, radiological and standard biochemical
and hormonal criteria and subsequently confirmed by his-
tological and immunocytochemical examination except for
most of the macroprolactinomas that were not surgically
treated. The control group was composed of 256 healthy
volunteers (150 males and 106 females, mean age±SD
36.8±13.7 years) recruited from Hospital and Faculty staff
and blood donors. Age differences between controls and
patients were not considered relevant as previous studies
have shown no correlation between age and genotype12,13.
All individuals were Caucasians. All gave informed con-
sent and the study was approved by the Hospital ethics
committee.
Genotype analysis
DNA was isolated from peripheral blood samples by
standard methods. Detection of the c.506,-1g>a transition,
corresponding to the recessive poor metabolizer allele
CYP2D6*4, was carried out by PCR amplification of ge-
nomic DNA, followed by restriction enzyme digestion with
BstN1 using previously published procedures14,15. This
allowed classification of individuals into extensive
(CYP2D6*1/CYP2D6*1), heterozygous extensive
(CYP2D6*1/CYP2D6*4) and poor (CYP2D6*4/
CYP2D6*4) metabolizers. GSTM1 and GSTT1 null geno-
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types were detected by PCR amplification that also in-
cluded fragments of the GSTM4 and beta-globin genes,
respectively, as internal controls, according to previous
published methods14,16,17. This method does not distin-
guish heterozygous null genotypes from wild-type ho-
mozygous.
Statistical analysis
Chi-squared tests were used to examine differences of
allele and genotype frequencies between patients and
controls. Fisher’s exact test was used when appropriate.
Statistical significance was set at a p value <0.05 and ad-
justed for the number of comparisons by use of the
Bonferroni correction. Analysis was also performed ac-
cording to tumor histological type.
RESULTS
Allele and genotype observed frequencies of the
CYP2D6, GSTM1 and GSTT1 genetic polymorphisms are
presented in tables I and II. The frequencies of the
CYP2D6*1/*1, CYP2D6*1/*4, CYP2D6*4/*4 genotypes
were similar in patients and in controls (χ22d.f.=4.88,
p=0.087). CYP2D6*1 and CYP2D6*4 allele frequencies
were 83.8%, 16.2% in cases and 78.3%, 21.7% in controls,
showing a significant difference between the two groups
(χ21d.f.=6.28, p=0.012). No differences were detected when
analyzed according to type of adenoma (table I).
Frequencies of the GSTM1*0/*0 and of the GSTT1*0/
*0 null genotypes were similar in cases and in controls. In
the different types of adenomas these frequencies were
also similar to the control group (table II).
Table I - CYP2D6 genotype and allele frequencies
  CYP2D6 genotypes (%) Alleles (%) 
 n *1/*1 *1/*4 *4/*4 *1 *4 
Control group 256 159 (62.1) 83 (32.4) 14 (5.5) 401 (78.3) 111 (21.7) 
All adenomas 235 165 (71.4) 64 (27.2) 6 (2.6)a 394 (83.8) 76 (16.2)b 
Null cell adenomas 65 47 (72.3) 17 (26.2) 1 (1.5) 111 (85.4) 19 (14.6) 
Somatotrophinomas 64 45 (70.3) 19 (29.7) 0 109 (85.2) 19 (14.8) 
Macroprolactinomas 58 37 (63.8) 18 (31. 0) 3 (5.2) 92 (79.3) 24 (20.7) 
Corticotrophinomas 27 19 (70.4) 6 (22.2) 2 (7.4) 44 (81.5) 10 (18.5) 
Gonadotrophinomas 12 10 (83.3) 2 (16.7) 0 22 (91.7) 2 (8.3) 
Thyrotrophinomas 2 2 0 0 4 0 
Pluri-hormonal adenomas 2 2 0 0 4 0 
Clinically non functioning 
adenomas 
5 3 2 0 8 2 
CYP2D6*1, active metabolizer; CYP2D6*4, poor metabolizer 
(a) vs. control group, χ21d.f.=2.98, p=0.084, (CYP2D6*4/*4 vs all others), χ22d.f.=4.88, 
p=0.087, (all genotypes);  
(b) vs. control group, χ21d.f.=6.28, p=0.012 
Table II - GSTM1 and GSTT1 genotype frequencies
  GSTM1 genotypes (%) GSTT1 genotypes (%)a 
 n (+) (0) (+) (0) 
Control group 256 110 (43.0) 146 (57.0) 209 (81.6) 47 (18.4) 
All adenomas 235 a 108 (46.0) 127 (54.0)b 193 (82.5) 41 (17.5)c  
Null cell adenomas 65 33 (50.8) 32 (49.2) 53 (81.5) 12 (18.5) 
Somatotrophinomas 64 28 (43.8) 36 (56.2) 53 (82.8) 11 (17.2) 
Macroprolactinomas 58 27 (46.6) 31 (53.4) 47 (82.5) 10 (17.5) 
Corticotrophinomas 27 10 (37.0) 17 (63.0) 23 (85.2) 4 (14.8) 
Gonadotrophinomas 12 9 (75.0) 3 (25.0) 10 (83.3) 2 (16.7) 
Thyrotrophinomas 2 0 2 2 0 
Pluri-hormonal adenomas 2 1 1 2 0 
Clinically nonfunctioning 
adenomas 
5 0 5 3 2 
(+) Gene present (homozygous or heterozygous); (0) Homozygous deletion (GSTM1*0/*0 
or GSTT1*0/*0) 
(a) In one case (macroprolactinoma) GSTT1 genotype was not possible to study 
 (b) vs. control group, χ21d.f.=0.33, p=0.57; (c) vs. control group, χ21d.f.=0.058, p=0.81  
DISCUSSION
In epidemiological studies, genetic polymorphisms of
genotoxic metabolizing enzymes have been correlated with
individual risk for the development of some tumors1,2. This
may result from different activities of the polymorphic
enzymes regarding activation or inactivation of different
carcinogens. Many tumors have been associated with
these polymorphisms, such as those from the lung, head
and neck, digestive system, breast, bladder, prostate, skin,
thyroid and hematological neoplasias8,14,18-26. However,
studies often present conflicting results which also seem
to vary according to ethnical/geographical context. In this
study, genotype frequencies of the CYP2D6, GSTM1 and
GSTT1 genes were described in 235 patients with different
pituitary adenomas to determine if any particular geno-
type was associated with a greater susceptibility for these
tumors or for specific histological types. The active
metabolizer allele (CYP2D6*1) was found at a higher fre-
quency in the group of patients. In a previous study, with
fewer patients, this frequency was also higher although
not significant11. While the functional significance of this
finding is unclear, this has also been reported for tumors
at other sites. Proposed mechanisms include increased
susceptibility due to metabolic activation of unidentified
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chemical carcinogens or linkage to another putative
tumour-causing gene25,26. No significant association was
found between GSTM1 and GSTT1 polymorphisms and
tumour risk. When the adenomas were divided according
to histological type there was no significant difference
between the different sub-groups and the control group
for the three genes studied. An increased frequency of
the GSTM1 null genotype has been previously reported
in prolactinomas but the sample studied was small (10). In
summary, these data suggest that CYP2D6 gene poly-
morphisms are associated with susceptibility for the de-
velopment of pituitary tumors and that the polymorphisms
of the GSTM1 and GSTT1 genes do not seem to be asso-
ciated with a greater risk for these tumors. However, fur-
ther studies are needed to analyze the effect according to
histological type and to determine if the association also
occurs in other populations with different ethnic/geo-
graphical backgrounds. This may allow the identification
of risk factors and contribute towards understanding the
molecular mechanisms involved in the process of pitui-
tary tumorigenesis.
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